BridgeMD
Clinical trial of patritumab deruxtecan in people with gastrointestinal cancers
EU CTIS ID: 2024-512442-41-00
What this study is testing
1. To evaluate the safety and tolerability of patritumab deruxtecan (HER3-DXd) 2. To evaluate the confirmed ORR per RECIST 1.1 as assessed by BICR (Cohort 1, Cohort 2, Cohort 4, and participants who received the preliminary RP2D in Cohort 3)
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Has one of the following cancers: • Unresectable or metastatic colorectal cancer • Advanced and/or unresectable biliary tract cancer (BTC) • Hepatocellular carcinoma (HCC) not amenable to locoregional therapy • Locally advanced unresectable or metastatic gastroesophageal cancer
- Has received prior therapy for the cancer
- Has recovered from any side effects due to previous cancer treatment
You likely can't join if
- Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
- Has clinically severe respiratory compromise (based on the investigator’s assessment) resulting from intercurrent pulmonary illnesses
- Has evidence of any leptomeningeal disease
- Has clinically significant corneal disease
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
The study team makes the final eligibility decision.
Where it's taking place
- Chile
- Korea, Republic of
- Israel
- China
- Turkey
- New Zealand
- Switzerland
- Thailand
- Australia
- Canada
- Taiwan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chile; Korea, Republic of; Israel; China; Turkey; New Zealand and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.